



## Commercial/Healthcare Exchange PA Criteria

*Effective: 6/9/2021*

**Prior Authorization:** FOTIVDA® (tivozanib)

**Products Affected:** FOTIVDA® (tivozanib) oral capsules

**Medication Description:**

Tivozanib is a tyrosine kinase inhibitor. In vitro cellular kinase assays demonstrated that tivozanib inhibits phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases including c-kit and PDGFR  $\beta$  at clinically relevant concentrations. In tumor xenograft models in mice and rats, tivozanib inhibited angiogenesis, vascular permeability, and tumor growth of various tumor cell types including human renal cell carcinoma.

**Covered Uses:** Advanced Renal cell carcinoma (RCC)

**Exclusion Criteria:**

N/A

**Required Medical Information:**

1. Diagnosis
2. Previous medications tried and failed

**Age Restrictions:** 18 years of age or older.

**Prescriber Restrictions:** Prescribed by or in consultation with an oncologist

**Coverage Duration:** 12 months for initial and continuation of therapy

**Other Criteria:**

### I. Initial Approval Criteria

(must meet all):

1. Patient has diagnosis of Renal cell carcinoma (RCC); AND
2. The disease is advanced; relapsed or refractory; AND
3. Patient is 18 years of age or older; AND
4. Patient has trial and failure of two or more prior systemic therapies; AND
5. The dose does not exceed 1.34 mg orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.

Last Rev. June 9, 2021



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

## II. Continued Therapy

1. Patient is responding positively to therapy, demonstrated by stabilization of the disease;; AND
2. Patient has not experienced unacceptable toxicity from the drug (e.g. cardiac failure, cardiac ischemia and arterial thromboembolic events, hypertension and hypertensive crisis, venous thromboembolic events, hemorrhagic events, proteinuria. etc)

### References:

1. Fotivda [package insert]. AVEO Pharmaceuticals, Inc. Boston, MA. March 2021.

### Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New policy	New policy	All	6/9/2021